Biotin-tagged probes for MMP expression and activation: Design, synthesis, and binding properties

Bioconjugate Chemistry

Volumn 20, Issue 4, 2009, Pages 719-727

  Dragoni, Elisa ^a   Calderone, Vito ^a   Fragai, Marco ^a   Jaiswal, Rahul ^a   Luchinat, Claudio ^a   Nativi, Cristina ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BINDING ENERGY; GLYCOPROTEINS;

AVIDIN-BIOTIN; BINDING PROPERTIES; BIOLOGICAL SAMPLES; DESIGN SYNTHESIS; HIGH AFFINITY; HIGHLY STABLES; MATRIX; METALLOPROTEINASES; NEW APPROACHES; SIMULTANEOUS FORMATION;

COENZYMES;

AVIDIN; BIOTIN; BIOTIN CHAIN TERMINATED INHIBITOR; ENZYME INHIBITOR; MATRIX METALLOPROTEINASE; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; BIOTINYLATION; DRUG DESIGN; DRUG SYNTHESIS; ENZYME ACTIVATION; IN VIVO STUDY; MOLECULAR PROBE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SAMPLE;

EID: 65249115262     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc8003827     Document Type: Article

References (51)

1. Giepmans, B. N. G., Adams, S. R., Ellisman, M. H., and Tsien, R. Y. (2006) The fluorescent toolbox for assessing protein location and function. Science 312, 217-224.
2. Blundell, T. L., Jhoti, H., and Abell, C. (2002) High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discoery 1, 45-54.
3. Johnson, S. L., and Pellecchia, M. (2006) Structure-and fragment-based approaches to protease inhibition. Curr. Top. Med. Chem. 6, 317-329.
4. Heckmann, D., Meyer, A., Marinelli, L., Zahn, G., Stragies, R., and Kessler, H. (2007) Probing integrin selectivity: rational design of highly active and selective ligands for the α β1 and α.5β3 integrin receptor. Angew. Chem., Int. Ed. 46, 3571-3574.
5. Jahnke, W., Blommers, M. J., Fernandez, C., Zwingelstein, C., and Amstutz, R. (2005) Strategies for the NMR-based identification and optimization of allosteric protein kinase inhibitors. ChemBioChem 6, 1607-1610.
6. Page-McCaw, A., Ewald, A. J., and Werb, Z. (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat. Rev. Mol. Cell Biol. 8, 221-233.
7. Parks, W. C., Wilson, C. L., and Lopez-Boado, Y. S. (2004) Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat. Rev. Immunol. 4, 617-629.
8. D'Alessio, S., Fibbi, G., Cinelli, M., Guiducci, S., Del Rosso, A., Margheri, F., Serrati, S., Pucci, M., Kahaleh, B., Fan, P. S., Annunziato, F., Cosmi, L., Liotta, F., Matucci-Cerinic, M., and Del Rosso, M. (2004) Matrix metalloproteinase 12-dependent cleavage of urokinase receptor in systemic sclerosis microvas-cular endothelial cells results in impaired angiogenesis. Arthritis Rheum. 50, 3275-3285.
9. Boire, A., Covic, L., Agarwal, A., Jacques, S., Sherifl, S., and Kuliopulos, A. (2005) PAR1 is a matrix metalloprotease-1 receptor that promotes invasion and tumorigenesis of breast cancer cells. Cell 120, 303-313.
10. Fragai, M., and Nesi, A. (2007) Substrate specificities of matrix metalloproteinase 1 in PAR-1 exodomain proteolysis. ChemBio-Chem 8, 1367-1369.
11. Knauper, V., Will, H., Lopez-Otin, C., Smith, B., Atkinson, S. J., Stanton, H., Hembry, R. M., and Murphy, G. (1996) Cellular mechanisms for human procollagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J. Biol. Chem. 271, 17124-17131.
12. Morrison, C. J., and Overall, C. M. (2006) TIMP Independence of matrix metalloproteinase (MMP)-2 activation by membrane type 2 (MT2)-MMP is determined by contributions of both the MT2-MMP catalytic and hemopexin C domains. J. Biol. Chem. 281, 26528-26539.
13. Ra, H. J., and Parks, W. C. (2007) Control of matrix metalloproteinase catalytic activity. Matrix Biol. 26, 587-596.
14. Overall, C. M., Tam, E., McQuibban, G. A., Morrison, C., Wallon, U. M., Bigg, H. F., King, A. E., and Roberts, C. R. (2000) Domain interactions in the gelatinase A·TIMP-2·MT1-MMP activation complex: the ectodomain of the 44-kDa form of membrane type-1 matrix metalloproteinase does not modulate gelatinase A activation. J. Biol. Chem. 275, 39497-39506.
15. Fingleton, B. (2007) Matrix metalloproteinases as valid clinical targets. Curr. Pharm. Des. 13, 333-346.
16. Skiles, J. W., Gonnella, N. C., and Jeng, A. Y. (2004) The design, structure, and clinical update of small molecular weight matrix metalloproteinase inhibitors. Curr. Med. Chem. 11, 2911-2977.
17. Egeblad, M., and Werb, Z. (2002) New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2, 161-174.
18. Bremer, C., Tung, C. H., Bogdanov, A., and Weissleder, R. (2002) Imaging of differential protease expression in breast cancers for detection of aggressive tumor phenotypes. Radiology 222, 814-818.
19. Lepage, M., Dow, W. C., Melchior, M., You, Y., Fingleton, B., Quarles, C. C., Pepin, C., Gore, J. C., Matrisian, L. M., and McIntyre, J. O. (2007) Non invasive detection of matrix metalloproteinase activity in vivo using a novel magnetic resonance imaging contrast agent with a solubility switch. Mol. Imagine 6, 393-W3.
20. David, A., Steer, D., Bregant, S., Devel, L., Makaritis, A., Beau, F., Yiotakis, A., and Dive, V. (2007) Cross-linking yield variation of a potent matrix metalloproteinase photoaffinity probe and consequences for functional proteomics. Aneew. Chem., Int. Ed. 46, 3275-3277.
21. Saghatelian, A., Jessani, N., Joseph, A., Humphrey, M., and Cravatt, B. F. (2004) Activity-based probes for the proteomic profiling of metalloproteases. Proc. Natl. Acad. Sci. U.S.A. 101, 10000-10005.
22. Bremer, C., Tung, C. H., and Weissleder, R. (2001) In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat. Med. 7, 743-748.
23. Faust, A., Waschkau, B., Waldeck, J., Holtke, C., Breyholz, H. J., Wagner, S., Kopka, K., Heindel, W., Schafers, M., and Bremer, C. (2008) Synthesis and evaluation of a novel fluorescent photoprobe for imaging matrix metalloproteinases. Bioconjugate Chem. 19, 1001-1008.
24. Wagner, S., Breyholz, H. J., Law, M. P., Faust, A., Holtke, C., Schroer, S., Haufe, G., Levkau, B., Schober, O., Schafers, M., and Kopka, K. (2007) Novel fluorinated derivatives of the broad-spectrum MMP inhibitors N-hydroxy-2(R)-[[(4-methox-yphenyl)sulfonyl](benzyl)-and (3-picolyl)-amino]-3- methyl-bu-tanamide as potential tools for the molecular imaging of activated MMPs with PET. J. Med. Chem. 50, 5752-5764.
25. Wagner, S., Breyholz, H. J., Faust, A., Holtke, C., Levkau, B., Schober, O., Schafers, M., and Kopka, K. (2006) Molecular imaging of matrix metalloproteinases in vivo using small molecule inhibitors for SPECT and PET. Curr. Med. Chem. 13, 2819-2838.
26. Uttamchandani, M., Wang, J., Li, J. Q., Hu, M. Y., Sun, H. Y., Chen, K. Y. T., Liu, K., and Yao, S. Q. (2007) Inhibitor fingerprinting of matrix metalloproteases using a combinatorial peptide hydroxamate library. J. Am. Chem. Soc. 129, 7848-7858.
27. Bertini, I., Calderone, V., Fragai, M., Luchinat, C., and Maletta, M. (2006) Snapshots of the reaction mechanism of matrix metalloproteinases. Angew. Chem., Int. Ed. 45, 7952-7955.
28. Bertini, I., Calderone, V., Fragai, M., Luchinat, C., Mangani, S., and Terni, B. (2003) X-ray structures of binary and ternary enzyme-product-inhibitor complexes of matrix metalloprotein-ases. Angew. Chem., Int. Ed. 42, 2673-2676.
29. Bertini, I., Calderone, V., Fragai, M., Luchinat, C., Mangani, S., and Terni, B. (2004) Crystal structure of the catalytic domain of human matrix metalloproteinase 10. J. Mol. Biol. 336, 707-716.
30. Bertini, I., Calderone, V., Fragai, M., Giachetti, A., Loconte, M., Luchinat, C., Maletta, M., Nativi, C., and Yeo, K. (2007) Exploring the subtleties of drug-receptor interactions: the case of matrix metalloproteinases. J. Am. Chem. Soc. 129, 2466-2475.
31. Bertini, I., Fragai, M., Lee, Y.-M., Luchinat, C., and Terni, B. (2004) Paramagnetic metal ions in ligand screening: The CoII matrix metalloproteinase 12. Angew. Chem., Int. Ed. 43, 2254-2256.
32. Calderone, V., Fragai, M., Luchinat, C., Nativi, C., Richichi, B., and Roelens, S. (2006) A high-affinity carbohydrate-containing inhibitor of matrix metalloproteinases. ChemMedChem I, 598-601.
33. Bertini, I., Fragai, M., Giachetti, A., Luchinat, C., Maletta, M., Parigi, G., and Yeo, K. J. (2005) Combining in silico tools and NMR data to validate protein-ligand structural models: application to matrix metalloproteinases. J. Med. Chem. 48, 7544-7559.
34. Fragai, M., Nativi, C., Richichi, B., and Venturi, C. (2005) Design in silico, synthesis and binding evaluation of a carbohydrate-based scaffold for structurally novel inhibitors of matrix metalloproteinases. ChemBioChem 6, 1345-1349.
35. Mannino, C., Nievo, M., Machetti, F., Papakyriakou, A., Fragai, M., and Guarna, A. (2006) Synthesis of bicyclic molecular scaffolds (BTAa): An investigation towards new selective MMP-12 inhibitors. Bioorg. Med. Chem. 14, 7392-7403.
36. Agrawal, A., Romero-Perez, D., Jacobsen, J. A., Villarreal, F. J., and Cohen, S. M. (2008) Zinc-binding groups modulate selective inhibition of MMPs. ChemMedChem 3, 812-820.
37. Puerta, D. T., and Cohen, S. M. (2004) A bioinorganic perspective on matrix metalloproteinase inhibition. Curr. Top. Med. Chem. 4, 1551-1573.
38. Pikul, S., Ohler, N. E., Ciszewski, G., Laufersweiler, M. C., Almstead, N. G., De, B., Natchus, M. G., Hsieh, L. C., Janusz, M. J., Peng, S. X., Branch, T. M., King, S. L., Taiwo, Y. O., and Mieling, G. E. (2001) Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. J. Med. Chem. 44, 2499-2502.
39. Wang, X. Q., Choe, Y. C., Craik, C. S., and Ellman, J. A. (2002) Design and synthesis of novel inhibitors of gelatinase B. Bioorg. Med. Chem. Lett. 12, 2201-2204.
40. Auge, F., Hornebeck, W., Decarme, M., and Laronze, J. Y. (2003) Improved gelatinase a selectivity by novel zinc binding groups containing galardin derivatives. Bioorg. Med. Chem. Lett. 13, 1783-1786.
41. Bertini, I., Calderone, V., Cosenza, M., Fragai, M., Lee, Y.-M., Luchinat, C., Mangani, S., Terni, B., and Turano, P. (2007) Solution structure of inhibitor-free human metalloelastase (MMP-12) indicates an internal conformational adjustment. J. Mol. Biol. 374, 1333-1344.
42. Bhaskaran, R., Palmier, M. O., Bagegni, N. A., Liang, X. Y., and Van Doren, S. R. (2007) Solution structure of inhibitor-free human metalloelastase (MMP-12) indicates an internal confor-mational adjustment. J. Mol. Biol. 374, 1333-1344.
43. Devel, L., Rogakos, V., David, A., Makaritis, A., Beau, F., Cuniasse, P., Yiotakis, A., and Dive, V. (2006) Development of selective inhibitors and substrate of matrix metalloproteinase-12. J. Biol. Chem. 281, 11152-11160.
44. Tochowicz, A., Maskos, K., Huber, R., Oltenfreiter, R., Dive, V., Yiotakis, A., Zanda, M., Bode, W., and Goettig, P. (2007) Crystal structures of MMP-9 complexes with five inhibitors: contribution of the flexible Arg424 side-chain to selectivity. J Mol. Biol. 371, 989-1006.
45. Lovejoy, B., Welch, A. R., Carr, S., Luong, C., Broka, C., Hendricks, R. T., Campbell, J. A., Walker, K. A. M., Martin, R., Van Wart, H., and Browner, M. F. (1999) Crystal structures of MMP-1 and-13 reveal the structural basis for selectivity of collagenase inhibitors. Nat. Struct. Biol. 6, 217-221.
46. Sabatino, G., Chinol, M., Paganelli, G., Papi, S., Chelli, M., Leone, G., Papini, A. M., De Luca, A., and Ginanneschi, M. (2003) A new biotin derivative-DOTA conjugate as a candidate for pretargeted diagnosis and therapy of tumors. J. Med. Chem. 46, 3170-3173.
47. Canales-Mayordomo, A., Fayos, R., Angulo, J., Ojeda, R., Martin-Pastor, M., Nieto, P. M., Martin-Lomas, M., Lozano, R., Gimenez-Gallego, G., and Jimenez-Barbero, J. (2006) Backbone dynamics of a biologically active human FGF-1 monomer, complexed to a hexasaccharide heparin-analogue, by 15N NMR relaxation methods. J. Biomol. NMR 35, 225-239.
48. Pellecchia, M., Sebbel, P., Hermanns, U., Wuthrich, K., and Glockshuber, R. (1999) Pilus chaperone FimC-adhesin FimH interactions mapped by TROSY-NMR. Nat. Struct. Biol. 6, 336-339.
49. D'Silva, L., Ozdowy, P., Krajewski, M., Rothweiler, U., Singh, M., and Holak, T. A. (2005) Monitoring the effects of antagonists on protein-protein interactions with NMR spectroscopy. J. Am. Chem. Soc. 12713220-13226.
50. Bertini, I., Calderone, V., Fragai, M., Jaiswal, R., Luchinat, C., Melikian, M., Mylonas, E., and Svergun, D. (2008) Evidence of reciprocal reorientation of the catalytic and hemopexin-like domains of full-length MMP-12. J. Am. Chem. Soc. 130, 7011-7021.
51. Bravman, T., Bronner, V., Lavie, K., Notcovich, A., Papalia, G. A., and Myszka, D. G. (2006) Exploring "one-shot" kinetics and small molecule analysis using the ProteOn XPR36 array biosensor. Anal. Biochem. 358, 281-288.